blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2344677

EP2344677 - METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASE SECONDARY TO MULTIPLE SCLEROSIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.02.2018
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  03.03.2017
FormerGrant of patent is intended
Status updated on  24.02.2017
Most recent event   Tooltip15.11.2019Lapse of the patent in a contracting state
New state(s): MK		published on 18.12.2019  [2019/51]
Applicant(s)For all designated states
Cambridge Enterprise Limited
The Old Schools Trinity Lane Cambridge
Cambridgeshire CB2 1TN / GB
[2011/29]
Inventor(s)01 / COLES, Alasdair, J.
University Neurology Unit
Department of Clinical Neurosciences
Levels 5&6 A Block (Box 165)
Addenbrookes Hospital
Cambridge CB2 2QQ / GB
02 / JONES, Joanne, L.
University Neurology Unit
Department of Clinical Neurosciences
Levels 5&6 A Block (Box 165)
Addenbrookes Hospital
Cambridge CB2 2QQ / GB
03 / COMPSTON, Alastair
University Neurology Unit
Department of Clinical Neurosciences
Levels 5&6 A Block (Box 165)
Addenbrookes Hospital
Cambridge CB2 2QQ / GB
 [2017/14]
Former [2011/29]01 / COLES, Alasdair, J.
University Neurology Unit Department of Clinical Neurosciences Levels 5&6 A Block (Box 165) Addenbrookes Hospital
Cambridge CB2 2QQ / GB
02 / JONES, Joanne, L.
University Neurology Unit Department of Clinical Neurosciences Levels 5&6 A Block (Box 165) Addenbrookes Hospital
Cambridge CB2 2QQ / GB
03 / COMPSTON, Alastair
University Neurology Unit Department of Clinical Neurosciences Levels 5&6 A Block (Box 165) Addenbrookes Hospital
Cambridge CB2 2QQ / GB
Representative(s)Titmus, Craig Edward, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2017/14]Evenson, Jane Harriet, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Former [2012/33]Evenson, Jane Harriet, et al
Mathys & Squire LLP 120 Holborn
London EC1N 2SQ / GB
Former [2011/29]Zvesper, Thomas, et al
Mathys & Squire LLP 120 Holborn
London EC1N 2SQ / GB
Application number, filing date09804308.608.10.2009
[2011/29]
WO2009IB07327
Priority number, dateUS20080197187P24.10.2008         Original published format: US 197187 P
US20080195658P08.10.2008         Original published format: US 195658 P
US20080198631P07.11.2008         Original published format: US 198631 P
[2011/29]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010041149
Date:15.04.2010
Language:EN
[2010/15]
Type: A2 Application without search report 
No.:EP2344677
Date:20.07.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 15.04.2010 takes the place of the publication of the European patent application.
[2011/29]
Type: B1 Patent specification 
No.:EP2344677
Date:05.04.2017
Language:EN
[2017/14]
Search report(s)International search report - published on:EP30.09.2010
ClassificationIPC:C12Q1/68
[2011/29]
CPC:
A61P5/14 (EP); C12Q1/6883 (EP,KR,US); G01N33/6869 (US);
A61K48/00 (KR); A61P25/00 (EP,US); A61P37/00 (EP,US);
A61P37/06 (EP); A61P7/00 (EP); A61P7/06 (EP);
C07K14/54 (KR); C12N15/1075 (US); C12Q1/6827 (US);
G01N33/6854 (KR); C12Q2600/106 (EP,KR,US); C12Q2600/156 (EP,KR,US);
C12Q2600/158 (EP,KR,US); C12Q2600/172 (EP,KR,US); G01N2800/285 (US);
G01N2800/52 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2017/14]
Former [2011/29]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR DIAGNOSE UND BEHANDLUNG EINER ZU MULTIPLER SKLEROSE SEKUNDÄREN AUTOIMMUNKRANKHEIT[2011/29]
English:METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASE SECONDARY TO MULTIPLE SCLEROSIS[2011/29]
French:PROCÉDÉS ET COMPOSITIONS POUR DIAGNOSTIC ET TRAITEMENT[2011/29]
Entry into regional phase04.05.2011National basic fee paid 
04.05.2011Designation fee(s) paid 
04.05.2011Examination fee paid 
Examination procedure04.05.2011Amendment by applicant (claims and/or description)
04.05.2011Examination requested  [2011/29]
28.01.2013Despatch of a communication from the examining division (Time limit: M06)
13.09.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
13.09.2013Reply to a communication from the examining division
19.06.2014Despatch of a communication from the examining division (Time limit: M06)
23.12.2014Reply to a communication from the examining division
09.07.2015Despatch of a communication from the examining division (Time limit: M06)
05.01.2016Reply to a communication from the examining division
24.10.2016Communication of intention to grant the patent
21.02.2017Fee for grant paid
21.02.2017Fee for publishing/printing paid
21.02.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17159235.5  / EP3241910
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.01.2013
Opposition(s)08.01.2018No opposition filed within time limit [2018/11]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
13.09.2013Request for further processing filed
13.09.2013Full payment received (date of receipt of payment)
Request granted
26.09.2013Decision despatched
Fees paidRenewal fee
25.10.2011Renewal fee patent year 03
11.10.2012Renewal fee patent year 04
14.10.2013Renewal fee patent year 05
14.10.2014Renewal fee patent year 06
12.10.2015Renewal fee patent year 07
11.10.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipMK05.04.2017
SM05.04.2017
IS05.08.2017
[2019/51]
Former [2018/13]SM05.04.2017
IS05.08.2017
Former [2017/51]IS05.08.2017
Cited inInternational search[I]   KRUPICA T ET AL: "Autoimmunity during lymphopenia: A two-hit model", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US LNKD- DOI:10.1016/J.CLIM.2006.04.569, vol. 120, no. 2, 1 August 2006 (2006-08-01), pages 121 - 128, XP024941263, ISSN: 1521-6616, [retrieved on 20060801] [I] 1-58,64-80 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.clim.2006.04.569
 [I]   VAN HEEL DAVID A ET AL: "A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21", NATURE GENETICS, vol. 39, no. 7, July 2007 (2007-07-01), pages 827 - 829, XP002577914, ISSN: 1061-4036 [I] 1-58,64-80 * abstract *

DOI:   http://dx.doi.org/10.1038/NG2058
 [A]   VOLLMER TIMOTHY L ET AL: "Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen", JOURNAL OF IMMUNOLOGY, vol. 174, no. 5, 1 March 2005 (2005-03-01), pages 2696 - 2701, XP002577915, ISSN: 0022-1767 [A] 1-58,64-80 * abstract *
 [A]   SPOLSKI R ET AL: "The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB LNKD- DOI:10.1016/J.COI.2008.02.004, vol. 20, no. 3, 1 June 2008 (2008-06-01), pages 295 - 301, XP022762935, ISSN: 0952-7915, [retrieved on 20080612] [A] 1-58,64-80 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.coi.2008.02.004
 [A]   SPOLSKI ROSANNE ET AL: "Interleukin-21: Basic biology and implications for cancer and autoimmunity", ANNUAL REVIEW OF IMMUNOLOGY, vol. 26, 8 November 2007 (2007-11-08), pages 57 - 79, XP002577916, ISSN: 0732-0582 [A] 1-58,64-80 * the whole document *

DOI:   http://dx.doi.org/10.1146/ANNUREV.IMMUNOL.26.021607.090316
 [A]   KHORUTS A ET AL: "A causal link between lymphopenia and autoimmunity", IMMUNOLOGY LETTERS, ELSEVIER BV, NL LNKD- DOI:10.1016/J.IMLET.2004.10.022, vol. 98, no. 1, 15 April 2005 (2005-04-15), pages 23 - 31, XP004799350, ISSN: 0165-2478 [A] 1-58,64-80 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.imlet.2004.10.022
 [XP]   JONES JOANNE L ET AL: "IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)", JOURNAL OF CLINICAL INVESTIGATION, vol. 119, no. 7, July 2009 (2009-07-01), pages 2052 - 2061, XP002577917, ISSN: 0021-9738 [XP] 1-58,64-80 * the whole document *

DOI:   http://dx.doi.org/10.1172/JCI37878
by applicant  COMPSTON; COLES, LANCET, vol. 372, 2008, pages 1502 - 17
   POLMAN; UITDEHAAG, BMJ321, 2000, pages 490 - 4
   COLES ET AL., JOURNAL OF NEUROLOGY, vol. 253, 2006, pages 98 - 108
   COLES ET AL., N. ENGL. J MED., vol. 359, 2008, pages 1786 - 1801 [I] 1-58,64-80 * abstract *
   COLES ET AL., LANCET, vol. 354, 1999, pages 1691 - 1695 [A] 1-58,64-80 * abstract *
   CHEN ET AL., MEDICINE (BALTIMORE), vol. 84, 2005, pages 98 - 106 [A] 1-58,64-80 * the whole document *
   DAIKELER, TYNDALL, BEST. PRACT. RES. CLIN. HAEMATOL., vol. 20, 2007, pages 349 - 360 [A] 1-58,64-80 * the whole document *
   JUBAULT ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 85, 2000, pages 4254 - 4257 [A] 1-58,64-80 * the whole document *
   TING; ZIEGLER; VOWELS, BONE MARROW TRANSPLANT., vol. 21, 1998, pages 841 - 843 [XP] 1-58,64-80 * the whole document *
   ZANDMAN-GODDARD; SHOENFELD, AUTOIMMUN. REV., vol. 1, 2002, pages 329 - 337
   KRUPICA ET AL., CLIN IMMUNOL, vol. 120, 2006, pages 121 - 128
   ALDERUCCIO ET AL., J EXP. MED, vol. 178, 1993, pages 419 - 426
   MCHUGH ET AL., J LMMUNOL, vol. 168, 2002, pages 5979 - 5983
   POWRIE ET AL., INT. IMMUNOL, vol. 5, 1993, pages 1461 - 1471
   SAKAGUCHI ET AL., J IMMUNOL, vol. 155, 1995, pages 1151 - 1164
   COX ET AL., EUR J IMMUNOL, vol. 35, 2005, pages 3332 - 3342
   BLOOM ET AL., AM J TRANSPLANT., vol. 8, 2008, pages 793 - 802
   DE KLEER, I. ET AL., BLOOD, vol. 107, 2006, pages 1696 - 1702
   ZHANG, H. ET AL., NAT MED, vol. 11, 2005, pages 1238 - 1243
   GE ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OFAMERICA, vol. 101, 2004, pages 3041 - 3046
   COLES ET AL., JNEUROLOGY, vol. 253, 2006, pages 98 - 108
   KING ET AL., CELL, vol. 117, 2004, pages 265 - 277
   GILLEECE ET AL., BLOOD, vol. 82, 1993, pages 807 - 812
   LUBLIN ET AL., NEUROLOGY, vol. 46, no. 4, 1996, pages 907 - 1 1
   MILLER ET AL., LANCET NEUROL, vol. 6, no. 10, 2007, pages 903 - 12
   FONTAINE, REV. NEUROL. (PARIS), vol. 157, 2001, pages 929 - 34
   CAPELLO ET AL., NEUROL. SCI., vol. 25, no. 4, 2004, pages 361 - 3
   HAINFELLNER ET AL., J. NEUROL. NEUROSURG. PSYCHIATR., vol. 55, no. 12, 1992, pages 1194 - 6
   COX ET AL., EUR. J. IMMUNOL., vol. 35, 2005, pages 3332 - 3342
   COLES ET AL., ANN. NEUROL., vol. 46, 1999, pages 296 - 304
   WEISS ET AL., EXPERT OPIN BIOL. THER., vol. 7, 2007, pages 1705 - 1721
   SIVAKUMAR ET AL., IMMUNOLOGY, vol. 112, 2004, pages 177 - 182
   MARLEAU ET AL., J LEUKOCYTE BIOL., vol. 78, 2005, pages 575 - 584
   ZENG ET AL., CURR. PROTOC. IMMUNOL., vol. 78, 2007, pages 6.30.1 - 6.30.8
   AUBRY ET AL., CYTOMETRY, vol. 37, 1999, pages 197 - 204
   LYONS ET AL., METHODS CELL BIOL., vol. 63, 2001, pages 375 - 398
   VENDRAME ET AL., EURJENDOCRINOL, vol. 152, 2005, pages 119 - 125
   VENDRAME ET AL., J CLIN ENDOCRINOL METABJC, 2006
   GE ET AL., P.N.A.S., vol. 101, 2004, pages 3041 - 3046
   GE ET AL., P.N.A.S., vol. 98, 2001, pages 1728 - 1733
   KASSIOTIS ET AL., JEXP. MED., vol. 197, 2003, pages 1007 - 1016
   CHO ET AL., J EXP. MED., vol. 192, 2000, pages 549 - 556
   GOLDRATH ET AL., JEXP. MED., vol. 192, 2000, pages 557 - 564
   MURALI-KRISHNA ET AL., J IMMUNOL, vol. 165, 2000, pages 1733 - 1737
   WU ET AL., NAT MED., vol. 10, 2004, pages 87 - 92
   GLAS ET AL., AM. J. GASTROENTEROL., vol. 104, 2009, pages 1737 - 1744
   LANCET NEUROL., vol. 7, 2008, pages 567 - 569
   YEO ET AL., ANN NEUROL, vol. 61, 2007, pages 228 - 236
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.